| Followers | 24 |
| Posts | 1403 |
| Boards Moderated | 0 |
| Alias Born | 01/27/2021 |
Thursday, March 03, 2022 4:42:58 PM
MY FIRST EVER HAPPY EXPERIENCE WITH A DOCTOR ABOUT VASCEPA:
Over the years, I've posted about all my bad experiences with New York and New Jersey doctors whenever I mention Vascepa and the things they've said: "Never heard of it." "Oh yeah, that's the fish oil drug for people with very high triglycerides." "Haven't heard of it, but I'll look it up." "Just eat more fish." "I'll write a prescription for Lovaza." "Fish oil supplements do the same thing and they're cheaper."
Whenever I'd pass along the comments, people on this board and others would almost always respond with: "Find another doctor!"
Except, as KM made clear last quarter when he said there are only about 6,000 U.S. doctors out of 750,000 doctors who regularly prescribe Vascepa, it's almost impossible to find doctors who know about and understand Vascepa. Literally, your odds of finding one are less than 1 percent!
So, long story longer, I found one of the 1 percent today! She's a doctor on 32nd Street in Manhattan and she's in a practice where I've gotten some of the ignorant quotes I cited above from other doctors. But she told me she regularly prescribes Vascepa and warns people that fish oil supplements are useless and might even harm their health since you can't know what's in them. She was surprised when I told her what some of her colleagues have said. I asked her to help educate them.
And I also learned that she has worked with Dr. Bhatt and knows all about Vascepa and assumed other doctors did too. "It's been around a while," she said.
Anyhow, I told her I'm happy she will remain my heart doctor and I was so happy to hear what she said about Vascepa and Dr. Bhatt that I felt like I had met a member of medical royalty. I'm already recommending her to friends.
Over the years, I've posted about all my bad experiences with New York and New Jersey doctors whenever I mention Vascepa and the things they've said: "Never heard of it." "Oh yeah, that's the fish oil drug for people with very high triglycerides." "Haven't heard of it, but I'll look it up." "Just eat more fish." "I'll write a prescription for Lovaza." "Fish oil supplements do the same thing and they're cheaper."
Whenever I'd pass along the comments, people on this board and others would almost always respond with: "Find another doctor!"
Except, as KM made clear last quarter when he said there are only about 6,000 U.S. doctors out of 750,000 doctors who regularly prescribe Vascepa, it's almost impossible to find doctors who know about and understand Vascepa. Literally, your odds of finding one are less than 1 percent!
So, long story longer, I found one of the 1 percent today! She's a doctor on 32nd Street in Manhattan and she's in a practice where I've gotten some of the ignorant quotes I cited above from other doctors. But she told me she regularly prescribes Vascepa and warns people that fish oil supplements are useless and might even harm their health since you can't know what's in them. She was surprised when I told her what some of her colleagues have said. I asked her to help educate them.
And I also learned that she has worked with Dr. Bhatt and knows all about Vascepa and assumed other doctors did too. "It's been around a while," she said.
Anyhow, I told her I'm happy she will remain my heart doctor and I was so happy to hear what she said about Vascepa and Dr. Bhatt that I felt like I had met a member of medical royalty. I'm already recommending her to friends.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
